Le rôle de plus en plus large des analogues de la somatostatine dans la thérapeutique
VALDES SOCIN, Hernan Gonzalo ; BETEA, Daniela ; PETROSSIANS, Patrick et al
Book published by Novartis (2002)Detailed reference viewed: 8 (1 ULg)
Extensive inflammatory pseudotumor of the pituitary.
Hansen, Isabelle ; Petrossians, Patrick ; Thiry, Albert et al
in Journal of Clinical Endocrinology and Metabolism (2001), 86(10), 4603-4610
A 40-yr-old female presented with an extensive lesion of the sellar area and the sphenoid sinus, spreading to the optic nerves and associated with pachymeningitis. Histological findings were consistent ... [more ▼]
A 40-yr-old female presented with an extensive lesion of the sellar area and the sphenoid sinus, spreading to the optic nerves and associated with pachymeningitis. Histological findings were consistent with an inflammatory pseudotumor, and steroid treatment allowed the disappearance of all the lesions. Inflammatory pseudotumors of the pituitary are very rare. This case appears unique with regard to the extension of the lesions and the dramatic response to medical treatment. The differential diagnosis of inflammatory lesions of the pituitary is difficult. It relies mainly on histological analysis and includes sarcoidosis, Wegener's granulomatosis, histiocytosis (Langerhans, Rosai-Dorfman, and Erdheim-Chester diseases) and lymphocytic hypophysitis. [less ▲]Detailed reference viewed: 32 (1 ULg)
ACTH silent adenoma shrinking under cabergoline.
Petrossians, Patrick ; ; Valdes Socin, Hernan Gonzalo et al
in European Journal of Endocrinology (2001), 144(1), 51-57
OBJECTIVES: The authors present a case report that proposes the use of cabergoline treatment in silent ACTH adenoma, an unusual member of the heterogeneous group of the so-called clinically non ... [more ▼]
OBJECTIVES: The authors present a case report that proposes the use of cabergoline treatment in silent ACTH adenoma, an unusual member of the heterogeneous group of the so-called clinically non-functioning pituitary adenomas. DESIGN: Following the clinical and radiological improvement of a recurrent silent ACTH adenoma in a 77-year-old patient treated with cabergoline (0.5 mg every 2 days for 2 years), in vitro studies of the original tumor were performed. METHODS: The original tumor from the patient was studied by in situ hybridization and dopamine D2 receptor autoradiography. It was compared with four macroprolactinomas and two macroadenomas from patients with Cushing's disease. RESULTS: The D2 receptor mRNA signal of the reported case was intense and of the same order of magnitude as that observed in control prolactinomas. Dopamine D2 receptor autoradiography was twice that of control corticotroph adenomas and was close to that observed in prolactinomas. CONCLUSIONS: This is the first description of an in vivo shrinkage of an ACTH silent adenoma under cabergoline. We demonstrate in vitro, the presence of D2 receptors in the primitive tumor in concentrations similar to those found in control prolactinomas. These results suggest that therapeutic trials with cabergoline might be undertaken in recurring cases of ACTH silent tumors and more generally, non-functioning pituitary adenomas. [less ▲]Detailed reference viewed: 29 (1 ULg)
Les hyperparathyroidies primaires: étiologies, diagnostic et traitement.
; ; Petrossians, Patrick et al
in Revue Médicale de Liège (2000), 55(11), 977-985
L'hyperparathyroïdie primaire est une maladie trop souvent méconnue. Son incidence est estimée à 28/100.000, soit environ 2.800 nouveaux cas par an en Belgique. La fréquence de l'hyperparathyroïdie ... [more ▼]
L'hyperparathyroïdie primaire est une maladie trop souvent méconnue. Son incidence est estimée à 28/100.000, soit environ 2.800 nouveaux cas par an en Belgique. La fréquence de l'hyperparathyroïdie augmente avec l'âge. En effet, 50 % des cas sont rencontrés après l'âge de 70 ans et 3 à 4 % des femmes au-delà de 70 ans sont touchées par l'affection. Cette affection peut être sporadique ou survenir dans un cadre étiologique plus complexe tel que les polyendocrinopathies ou la neurofibromatose. L'attention vers ce diagnostic doit être attirée par une symptomatologie, souvent bâtarde, de fatigue (parfois isolée), de polyurie, de polydipsie, d'hypertension artérielle ou la présence de lithiases rénales. Lorsque le diagnostic d'hyperparathyroïdie est renteu, il convient de localiser la ou les glande(s) pathologique(s) et de définir le contexte étiologique qui pourra déterminer le choix thérapeutique le plus approprié. Une étude biologique simple sera réalisée devant toute suspicion d'hyperparathyroïdie. Dans certains cas, le diagnostic sera aidé par la réalisation d'un test de surcharge calcique qui peut permettre de confirmer l'hyperparathyroïdie et d'apprécier son degré d'autonomisation. [less ▲]Detailed reference viewed: 70 (3 ULg)
Malignant prolactinoma discovered by D2 receptor imaging.
Petrossians, Patrick ; ; et al
in Journal of Clinical Endocrinology and Metabolism (2000), 85(1), 398-401Detailed reference viewed: 16 (0 ULg)
Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients.
; ; et al
in Journal of Clinical Endocrinology and Metabolism (1999), 84(7), 2518-22
Cabergoline is a new long-acting dopamine agonist that is very effective and well tolerated in patients with pathological hyperprolactinemia. The aim of this study was to examine, in a very large number ... [more ▼]
Cabergoline is a new long-acting dopamine agonist that is very effective and well tolerated in patients with pathological hyperprolactinemia. The aim of this study was to examine, in a very large number of hyperprolactinemic patients, the ability to normalize PRL levels with cabergoline, to determine the effective dose and tolerance, and to assess the effect on clinical symptoms, tumor shrinkage, and visual field abnormalities. We also evaluated the effects of cabergoline in a large subgroup of patients with bromocriptine intolerance or -resistance. We retrospectively reviewed the files of 455 patients (102 males and 353 females) with pathological hyperprolactinemia treated with cabergoline in 9 Belgian centers. Among these patients, 41% had a microadenoma; 42%, a macroadenoma; 16%, idiopathic hyperprolactinemia; and 1%, an empty sella. The median pretreatment serum PRL level was 124 microg/L (range, 16-26,250 microg/L). A subgroup of 292 patients had previously been treated with bromocriptine, of which 140 showed bromocriptine intolerance and 58 showed bromocriptine resistance. Treatment with cabergoline normalized serum PRL levels in 86% of all patients: in 92% of 244 patients with idiopathic hyperprolactinemia or a microprolactinoma and in 77% of 181 macroadenomas. Pretreatment visual field abnormalities normalized in 70% of patients, and tumor shrinkage was seen in 67% of cases. Side effects were noted in 13% of patients, but only 3.9% discontinued therapy because of side effects. The median dose of cabergoline at the start of therapy was 1.0 mg/week but could be reduced to 0.5 mg/week once control was achieved. Patients with a macroprolactinoma needed a higher median cabergoline dose, compared with those with idiopathic hyperprolactinemia or a microprolactinoma: 1.0 mg/week vs. 0.5 mg/week, although a large overlap existed between these groups. Twenty-seven women treated with cabergoline became pregnant, and 25 delivered a healthy child. One patient had an intended abortion and another a miscarriage. In the patients with bromocriptine intolerance, normalization of PRL was reached in 84% of cases, whereas in the bromocriptine-resistant patients, PRL could be normalized in 70%. We confirmed, in a large-scale retrospective study, the high efficacy and tolerability of cabergoline in the treatment of pathological hyperprolactinemia, leaving few patients with unacceptable side effects or inadequate clinical response. Patients with idiopathic hyperprolactinemia or a microprolactinoma, on average, needed only half the dose of cabergoline as those with macroprolactinomas and have a higher chance of obtaining PRL normalization. Cabergoline also normalized PRL in the majority of patients with known bromocriptine intolerance or -resistance. Once PRL secretion was adequately controlled, the dose of cabergoline could often be significantly decreased, which further reduced costs of therapy. [less ▲]Detailed reference viewed: 58 (2 ULg)
Familial Acromegaly: Case Report and Review of the Literature
Verloes, Alain ; Stevenaert, Achille ; et al
in Pituitary (1999), 1(3-4), 273-277
Familial acromegaly is an exceptional clinical entity when not associated with features of multiple endocrine neoplasia type 1 (MEN1). We report here 3 pedigrees in each of which 2 patients have been ... [more ▼]
Familial acromegaly is an exceptional clinical entity when not associated with features of multiple endocrine neoplasia type 1 (MEN1). We report here 3 pedigrees in each of which 2 patients have been shown to develop acromegaly. In 4 patients, clinical follow-up, and biological screening allowed to confidently exclude MEN1. Absence of mutation in the MEN1 gene after direct DNA analysis in 2 pedigrees reinforces the conviction that the families do not have MEN1. In families 1 and 2, diagnosis was made at a very early age and voluminous adenomas with suprasellar expansion were already present at the time of diagnosis. We review the 20 previous reports of familial acromegaly, some of them questionable. Our 3 families, combined with some other published pedigrees, allow the delineation of a familial form of acromegaly, distinct from MEN1. Dominant inheritance with reduced, age-dependant penetrance is the most parsimonious model to explain the recurrences. Gs protein pathway could be the site of action of the gene responsible of familial acromegaly, but no data have been published to sustain or reject this hypothesis. [less ▲]Detailed reference viewed: 26 (1 ULg)
Cabergoline in the treatment of Hyoerprolactinemia : A study in 455 patients
; ; et al
in 9th Meeting and workshop of the European Neuroendocrine Association - Abstract book (1999)Detailed reference viewed: 3 (0 ULg)
Familial Acromegaly : Case report and review of the litterature
Beckers, Albert ; Stevenaert, Achille ; et al
in The 6th International Pituitary Congress - Abstract book (1999)Detailed reference viewed: 4 (0 ULg)
Insuffisance hypophysaire et amaurose subaiguës causées par une pseudotumeur inflammatoire extensive du sinus sphénoïde
Hansen, Isabelle ; Petrossians, Patrick ; et al
in XVI Congrès de la Société Française d'Endocrinologie - Abstract book (1998)Detailed reference viewed: 43 (0 ULg)
An epidemiological survey of 783 patients who underwent pituitary surgery in a single Centre over a 25-year periods
Beckers, Albert ; Petrossians, Patrick ; Stevenaert, Achille
in 24th International Symposium on GH and growth factors in Endocrinology and Metabolism - Abstract book (1997)Detailed reference viewed: 5 (0 ULg)
Growth hormone secretion during pregnancy in an acromegalic woman
Petrossians, Patrick ; ; et al
in 10th international Congress of Endocrinology - Abstract book (1996)Detailed reference viewed: 6 (0 ULg)
Treatment of macroprolactinomas with the long-acting and repeatable form of bromocriptine: a report on 29 cases.
Beckers, Albert ; Petrossians, Patrick ; et al
in Journal of Clinical Endocrinology and Metabolism (1992), 75(1), 275-80
Twenty-nine patients with macroprolactinomas were treated by monthly intramuscular injections of the long-acting and repeatable form of bromocriptine (Parlodel-LAR) in doses ranging from 50-150 mg. They ... [more ▼]
Twenty-nine patients with macroprolactinomas were treated by monthly intramuscular injections of the long-acting and repeatable form of bromocriptine (Parlodel-LAR) in doses ranging from 50-150 mg. They were divided into two groups: group I consisted of 22 patients who received Parlodel LAR before transsphenoidal adenomectomy; group II was composed of 7 patients with earlier neurosurgery and of 2 patients from group I not cured by transsphenoidal adenomectomy. Duration of therapy varied from 1-12 months, and a total of 104 injections was given. At nadir day, serum PRL levels were situated between less than 1% and 43% of pretreatment values. At day 28 after the first injection, serum PRL levels varied between less than 1% to 139% of initial values. No difference could be detected between the two groups regarding the percent of PRL inhibition. Long-term treatment with Parlodel-LAR resulted in a sustained inhibition of PRL secretion, except for 1 case. Resumption of menstrual cycles occurred in 4 out of 15 women and correction of hypogonadism in 4 out of 14 men. Amelioration of disturbed visual fields was recorded in 3 out of 8 patients. Diminution of the adenoma volume was radiologically documented in 14 out of 22 cases. Only few and mild side effects were recorded. One patient with partial adrenal deficiency suffered from a syncope, but this was prevented by hydrocortisone supplementation during the subsequent Parlodel-LAR administration. In conclusion, Parlodel-LAR proved effective in the treatment of macroprolactinomas, achieving rapid inhibition of PRL secretion, and in some patients amelioration of hypopituitarism, reduction in tumor size, and improvement in visual fields, and caused no serious side effects. It is a valuable preparation to surgery and can also be used in long-term medical therapy. [less ▲]Detailed reference viewed: 5 (0 ULg)
Treatment of macroprolactinomas with the long-acting and repeatable form of bromocriptine (PARLODEL LAR) : a report on 29 cases.
Petrossians, Patrick ; Beckers, Albert ; et al
Conference (1992)Detailed reference viewed: 13 (0 ULg)
Treatment of macroprolactinomas with the long-acting and repeatable form of bromocriptine (Parlodel LAR): report on 29 cases.
Beckers, Albert ; Petrossians, Patrick ; et al
Conference (1992)Detailed reference viewed: 9 (0 ULg)
The treatment of macroprolactinomas with long acting repeatable bromocriptine.
Beckers, Albert ; ; Petrossians, Patrick et al
in Journal of Endocrinological Investigation (1990)
Tratamiento farmacologico de la hiperprolactinemia
Petrossians, Patrick ; Stevenaert, Achille ; Beckers, Albert
in Hiperprolactinemias : Avances en el Diagnostico y tratamiento de las hiperprolactinemias (1989)Detailed reference viewed: 15 (0 ULg)
Die medikamentöse behandlung von prolaktinomen mit Cabergolin
Petrossians, Patrick ; Stevenaert, Achille ; Beckers, Albert
in Aktuelle Diagnostik und therapie bei Störungen der Prolaktinsekretin (1989)Detailed reference viewed: 9 (0 ULg)